Genomic Influence of a Key Transcription Factor in Male Glandular Malignancy

Basic Information

• Paper ID: 2510.11959
• Title: Genomic Influence of a Key Transcription Factor in Male Glandular Malignancy
• Authors: Allison Powell (University of South Alabama), Paramahansa Pramanik (University of South Alabama)
• Classification: q-bio.QM (Quantitative Methods)
• Publication Date: October 13, 2025
• Paper Link: https://arxiv.org/abs/2510.11959

Abstract

Prostate cancer (PCa) remains a significant global health burden for men, particularly regarding the lethality of its aggressive variants. Despite therapeutic advances that have improved survival rates for many patients, high-grade PCa continues to be a leading cause of cancer-related mortality. Emerging evidence indicates that the MYB proto-oncogene is a key factor promoting tumor progression, therapeutic resistance, and disease recurrence. Notably, distinct expression patterns have been observed, with MYB levels in tumor tissues of Black men significantly higher than in White men, potentially providing insight into the racial disparities documented in clinical outcomes. This study investigates the associations between MYB expression and key oncogenic characteristics, including androgen receptor (AR) signaling, disease progression, and biochemical recurrence risk.

Research Background and Motivation

Core Research Questions

1. Molecular mechanisms underlying racial disparities in prostate cancer: Black men exhibit significantly higher incidence and mortality rates of prostate cancer compared to other racial groups, yet the underlying molecular mechanisms remain unclear
2. Limitations in biochemical recurrence prediction: Traditional prognostic indicators (such as Gleason score and PSA level) demonstrate insufficient predictive capacity for individual patient outcomes
3. Need for precision medicine: Lack of effective molecular biomarkers to guide individualized treatment strategies

Research Significance

• Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in American men
• Prostate cancer mortality rates in Black men are more than twice those in White men
• Racial disparities cannot be entirely attributed to differences in healthcare access or socioeconomic factors
• Identification of intrinsic biological differences is necessary to achieve precision medicine

Limitations of Existing Approaches

• Traditional prognostic markers (Gleason score, PSA, clinical stage) have limited predictive capacity
• Lack of research addressing race-specific molecular differences
• Insufficient understanding of the MYB-AR signaling axis in prostate cancer progression

Core Contributions

1. Revealed racial disparities in MYB expression: First systematic demonstration that MYB expression levels in prostate cancer tissues are significantly higher in Black patients compared to White patients
2. Established MYB as a predictor of biochemical recurrence: Demonstrated strong negative correlation between MYB expression and biochemical recurrence time (r = -0.6659, p < 0.0001)
3. Elucidated the MYB-AR signaling axis: Identified positive correlation between MYB and androgen receptor expression, suggesting synergistic pro-oncogenic effects
4. Constructed a multimodal analysis framework: Integrated histopathological examination, quantitative digital imaging, and public transcriptomic dataset analysis
5. Developed predictive models and visualization tools: Constructed BCR prediction models incorporating nomograms and calibration curves

Methodology Details

Task Definition

Investigation of MYB proto-oncogene expression patterns in prostate cancer, particularly its associations with tumor grade, pathological stage, racial disparities, and biochemical recurrence, to assess its potential as a prognostic biomarker and therapeutic target.

Study Design and Sample

• Retrospective cohort study: 105 prostate cancer patients, 35 benign prostatic hyperplasia (BPH) cases, 38 high-grade prostatic intraepithelial neoplasia (HGPIN) cases
• Racial stratification: 50 White and 55 Black prostate cancer patients
• Clinicopathological information: Patient age, Gleason score, pathological stage, pre-treatment PSA level

Immunohistochemical Analysis

1. Tissue processing: Formalin-fixed paraffin-embedded (FFPE) specimens
2. Antigen retrieval: Heat-induced epitope retrieval
3. Antibody incubation: MYB and AR-specific antibodies incubated overnight at 4°C
4. Signal detection: Biotin-streptavidin complex (ABC) reaction with DAB chromogen

H-Score Calculation

MYB and AR expression were assessed using a semi-quantitative H-score system:

$H\text{score} = \sum_{i=1}^{3} P_i \times I_i$

where $P_i$ represents the percentage of cells with different staining intensities, and $I_i$ represents the corresponding intensity score (1+ = weak, 2+ = moderate, 3+ = strong).

Digital Image Analysis

• Scanning: Aperio CS2 scanner at 20× magnification
• Analysis software: Aperio ImageScope software
• Algorithm: Nuclear image analysis algorithm for quantitative assessment of staining intensity

Statistical Analysis Methods

1. Correlation analysis: Pearson correlation coefficients to assess relationships between MYB, AR, Gleason score, PSA, and BCR time
2. Survival analysis: Kaplan-Meier survival curves and Cox proportional hazards models
3. Group comparisons: Mann-Whitney U test (two-group comparisons) and Kruskal-Wallis test (multiple group comparisons)
4. Network analysis: Exponential random graph models (ERGM) for analyzing patient similarity networks

Experimental Setup

Data Sources

1. Tissue specimens: Retrospectively collected prostate tissue samples
2. Public databases: The Cancer Genome Atlas (TCGA) data
3. Clinical data: Patient clinicopathological characteristics and follow-up information

Evaluation Metrics

• H-score: Semi-quantitative assessment of immunohistochemical staining intensity
• Biochemical recurrence (BCR): PSA elevation following radical prostatectomy
• Correlation coefficients: Assessment of association strength between variables
• Survival probability: BCR-free survival rate

Technical Platforms

• Statistical software: R (version 4.4.2), GraphPad Prism 8.0
• Visualization tools: Multiple chart types (box plots, scatter plots, heat maps, network graphs, etc.)

Experimental Results

Major Findings

Tissue-Specific MYB Expression

• Benign tissue: Sparse MYB staining in BPH, predominantly weak staining
• Precancerous lesions: HGPIN shows focal increases in staining intensity
• Malignant tissue: Prostate cancer tissues display significant nuclear MYB expression, particularly in high Gleason score tumors

Racial Disparity Analysis

Key Finding: MYB H-scores in prostate cancer tissues of Black patients are significantly higher than in White patients (p = 0.0046)

• This disparity exists in both low-intermediate and high-grade tumors
• Supports the hypothesis that MYB may promote more aggressive clinical phenotypes in Black men

Associations Between MYB and Clinicopathological Features

1. Tumor grade: MYB expression increases with Gleason score
2. Pathological stage: Tumors with extraprostatic extension (pT3/pT4) show higher MYB levels compared to organ-confined tumors (pT2)
3. Biochemical recurrence prediction: MYB expression shows strong negative correlation with BCR time (r = -0.6659, p < 0.0001)

MYB-AR Signaling Axis

• MYB expression positively correlates with AR expression (r = 0.3638, p = 0.0001)
• Stronger correlation in White cohort (r = 0.5150) versus Black cohort (r = 0.3956)
• Suggests potential racial differences in AR-mediated signaling pathways

Survival Analysis Results

Kaplan-Meier Analysis

• MYB expression quartile stratification shows earliest BCR-free survival decline in Q4 group (highest expression)
• Although trend is evident, inter-group differences did not reach statistical significance (p = 0.19)

Cox Regression Model

Constructed adjusted survival curves demonstrating the impact of race-tumor stage combined classification on recurrence risk

Predictive Model Development

Nomogram Development

Constructed nomograms based on Cox proportional hazards models to predict 1-year, 3-year, and 5-year BCR-free survival rates

Model Calibration

• 1-year prediction: High concordance between model predictions and observed data
• 3-year prediction: Maintains reasonable concordance with minor deviations
• 5-year prediction: Long-term predictive accuracy decreases

Related Work

Molecular Biomarker Research in Prostate Cancer

• Limitations of traditional biomarkers (PSA, Gleason score)
• Application of emerging molecular biomarkers in risk stratification
• Role of racial disparities in prostate cancer prognosis

MYB Research in Cancer

• Classical role of MYB in hematologic malignancies
• Emerging role of MYB in solid tumors
• Mechanistic studies of MYB-AR signaling axis in prostate cancer

Precision Medicine Applications in Prostate Cancer

• Development of individualized treatment strategies
• Need for race-specific biomarkers
• Value of multi-omics integration in prognostic prediction

Conclusions and Discussion

Main Conclusions

1. MYB is a key driver of prostate cancer progression: Expression levels closely correlate with tumor aggressiveness characteristics
2. Significant racial disparities exist: Consistently elevated MYB expression in Black patients may explain prognostic differences
3. MYB has strong predictive value: Superior to traditional biomarkers in predicting biochemical recurrence
4. MYB-AR axis is a potential therapeutic target: Synergistic effects of both provide theoretical basis for targeted therapy

Clinical Implications

• Optimized risk stratification: MYB expression can improve accuracy of patient risk stratification
• Individualized treatment: Provides targeted treatment strategies for high-risk racial groups
• Early intervention: Identifies high-risk recurrence patients for early intervention

Limitations

1. Limited sample size: Relatively small cohort may affect statistical power
2. Retrospective design: Potential for selection bias
3. Insufficient mechanistic studies: Lack of in-depth exploration of MYB regulatory mechanisms
4. Need for validation: Requires large-scale multicenter studies for validation

Future Directions

1. Mechanistic studies: In-depth exploration of epigenetic regulatory mechanisms of MYB overexpression
2. Therapeutic development: Development of MYB-specific inhibitors or gene editing therapies
3. Clinical trials: Design precision medicine clinical trials incorporating MYB expression levels
4. Multi-omics integration: Combine genomic, transcriptomic, and proteomic data

In-Depth Evaluation

Strengths

1. Reasonable study design: Multimodal approach with scientifically rigorous methodology
2. Strong clinical relevance: Focuses on important clinical problems and racial health disparities
3. Methodological innovation: Combines traditional pathology with modern digital imaging techniques
4. Comprehensive statistical analysis: Employs multiple statistical methods and visualization techniques
5. High practical value: Provides practical predictive models and clinical decision-making tools

Limitations

1. Relatively limited sample size: 105 prostate cancer patients may limit statistical power
2. Lack of prospective validation: All analyses based on retrospective data requiring prospective validation
3. Limited mechanistic exploration: Insufficient discussion of MYB regulatory mechanisms and molecular basis of racial differences
4. Insufficient treatment guidance: Lacks specific recommendations for MYB expression-guided treatment selection

Impact Assessment

1. Academic contribution: Provides important molecular evidence for prostate cancer racial disparity research
2. Clinical value: Likely to improve identification and management of high-risk patients
3. Social significance: Helps address health equity issues in cancer treatment
4. Research advancement: Establishes foundation for subsequent MYB-targeted therapeutic research

Applicable Scenarios

1. Clinical risk assessment: For prognostic assessment and risk stratification of prostate cancer patients
2. Racial disparity research: Provides reference for racial disparity research in other cancer types
3. Precision medicine practice: Guides individualized treatment decision-making
4. Drug development: Provides theoretical support for MYB-targeted drug development

References

The paper cites 36 references covering multiple aspects including prostate cancer molecular mechanisms, racial disparities, MYB function, and statistical methods, with comprehensive and authoritative citations.

Overall Assessment: This is a high-quality translational medical research study that successfully integrates basic molecular biology research with clinical practice needs. The research not only provides important scientific discoveries but also possesses direct clinical application value, particularly in addressing racial disparities in prostate cancer treatment.